S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
NASDAQ:HZNP

Horizon Therapeutics Public (HZNP) Stock Forecast, Price & News

$90.35
+1.01 (+1.13%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$87.88
$90.87
50-Day Range
$83.26
$116.36
52-Week Range
$82.51
$120.54
Volume
1.85 million shs
Average Volume
1.84 million shs
Market Capitalization
$20.77 billion
P/E Ratio
24.75
Dividend Yield
N/A
Beta
1.11
30 days | 90 days | 365 days | Advanced Chart
Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

Horizon Therapeutics Public logo

About Horizon Therapeutics Public

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:HZNP
CUSIP
44047T10
Employees
1,890
Year Founded
2008

Sales & Book Value

Annual Sales
$3.23 billion
Cash Flow
$6.58 per share
Book Value
$20.96 per share

Profitability

Net Income
$534.49 million
Pretax Margin
21.40%

Debt

Price-To-Earnings

Miscellaneous

Free Float
224,137,000
Market Cap
$20.77 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/20/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.55 out of 5 stars

Medical Sector

109th out of 1,420 stocks

Pharmaceutical Preparations Industry

43rd out of 679 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -













Horizon Therapeutics Public (NASDAQ:HZNP) Frequently Asked Questions

Is Horizon Therapeutics Public a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 1 sell rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Horizon Therapeutics Public stock.
View analyst ratings for Horizon Therapeutics Public
or view top-rated stocks.

When is Horizon Therapeutics Public's next earnings date?

Horizon Therapeutics Public is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Horizon Therapeutics Public
.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Wednesday, May, 4th. The biopharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.14 by $0.20. The biopharmaceutical company had revenue of $885.25 million for the quarter, compared to the consensus estimate of $866.39 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 32.08% and a net margin of 22.87%. The business's revenue was up 158.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.03 earnings per share.
View Horizon Therapeutics Public's earnings history
.

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.90 billion-$4.00 billion, compared to the consensus revenue estimate of $3.98 billion.

What price target have analysts set for HZNP?

8 brokers have issued 1-year target prices for Horizon Therapeutics Public's shares. Their forecasts range from $121.00 to $168.00. On average, they anticipate Horizon Therapeutics Public's share price to reach $137.38 in the next year. This suggests a possible upside of 52.0% from the stock's current price.
View analysts' price targets for Horizon Therapeutics Public
or view top-rated stocks among Wall Street analysts.

Who are Horizon Therapeutics Public's key executives?
Horizon Therapeutics Public's management team includes the following people:
What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public CEO Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among Horizon Therapeutics Public's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.84%), BlackRock Inc. (6.02%), Capital International Investors (3.08%), Paulson & CO. Inc. (2.44%), State Street Corp (2.38%) and Bank of New York Mellon Corp (1.71%). Company insiders that own Horizon Therapeutics Public stock include Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends for Horizon Therapeutics Public
.

Which major investors are selling Horizon Therapeutics Public stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Woodline Partners LP, William Blair Investment Management LLC, Paulson & CO. Inc., Bank of Montreal Can, Healthcare of Ontario Pension Plan Trust Fund, Scout Investments Inc., and Renaissance Technologies LLC. Company insiders that have sold Horizon Therapeutics Public company stock in the last year include Andy Pasternak, Barry Moze, Brian K Beeler, Elizabeth HZ Thompson, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Paul W Hoelscher, and Timothy P Walbert.
View insider buying and selling activity for Horizon Therapeutics Public
or view top insider-selling stocks.

Which major investors are buying Horizon Therapeutics Public stock?

HZNP stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Assenagon Asset Management S.A., BlackRock Inc., Goldman Sachs Group Inc., Sumitomo Mitsui Trust Holdings Inc., Arrowstreet Capital Limited Partnership, Deerfield Management Company L.P. Series C, and Bank of New York Mellon Corp.
View insider buying and selling activity for Horizon Therapeutics Public
or or view top insider-buying stocks.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $90.35.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public has a market capitalization of $20.77 billion and generates $3.23 billion in revenue each year. The biopharmaceutical company earns $534.49 million in net income (profit) each year or $3.65 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

Horizon Therapeutics Public employs 1,890 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?

The following companies are subsidiares of Horizon Therapeutics Public: Andromeda Biotech Limited, Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, HZNP USA LLC, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Aon Limited, Horizon Pharma Dó Limited, Horizon Pharma Israel Holding Corp. Ltd, Horizon Pharma Rheumatology LLC, Horizon Pharma Trí Limited, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Schweiz GmbH, Horizon Therapeutics Services LLC, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, and River Vision Development Corp..

When was Horizon Therapeutics Public founded?

Horizon Therapeutics Public was founded in 2008.

What is Horizon Therapeutics Public's official website?

The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.

How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at [email protected], or via fax at 224-383-3001.

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.